Aitia Bio’s Colin Hill, writing in the November 2024 issue of DIA’s Global Forum magazine outlines why “digital twins” – virtual models of patients, systems, or devices that simulate real-world…
Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region. …
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
With the naming of Armida Zuñiga as head of the country’s regulatory body COFEPRIS, new Mexican president Claudia Sheinbaum has concluded the new government’s healthcare appointments and begun advancing her…
An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue…
Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of…
Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated…
The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win…
At this year’s FT Live Global Pharma and Biotech Summit, Takeda’s President and CEO Christophe Weber spoke about the increased challenges for healthcare systems. Weber acknowledged that as cost pressures…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no fewer than four…
With lower labour costs than mainland US, but the same regulatory framework and straightforward market access, Puerto Rico has long presented a compelling value proposition for pharmaceutical manufacturing, a sector…
See our Cookie Privacy Policy Here
